Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry significant risk, but their late-stage pipelines and upcoming catalysts have convinced institutional investors to build substantial positions. All four trade with unanimous or near-unanimous Buy ratings, a rare show of conviction in volatile biotech.
This post appeared first on 24/7 Wall St.